MedPath

Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact Lens

Not Applicable
Completed
Conditions
Myopia and Hyperopia and Presbyopia
Interventions
Device: new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens
Registration Number
NCT05660577
Lead Sponsor
Bausch & Lomb Incorporated
Brief Summary

The objective of this study is to evaluate the product performance of a new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens, when worn by current soft contact lens wearers on a daily disposable wear basis

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
301
Inclusion Criteria
  • Subjects must be age 40 years or older on the date the ICF is signed and have the capacity to provide voluntary informed consent
  • Subjects must be willing and able to comply with all treatment and follow-up/study procedures, as well as willing and able to refrain from using any contact lenses other than those provided for the duration of the study
  • Subjects must be correctable through spherocylindrical refraction to 42 letters (0.1 logMAR) or better (distance, high contrast) in each eye
  • Subjects must have clear central corneas and be free of any anterior segment disorders
  • Subject must wear their current lenses for a minimum of 12 hours per day at least four days per week
  • Subjects must habitually wear a multifocal lens in each eye
  • Subjects must be an adapted multifocal soft contact lens wearer for a minimum of 6 months
  • Subjects must require distance lens correction from +3.00 to -6.00 D in each eye
  • Subjects must be presbyopic and require near add correction from +0.75 to +2.50 D in each eye
  • Subjects must have access to an internet connection to complete an online survey and be able to receive text message
Read More
Exclusion Criteria
  • Subjects participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or plan to do so during the period of study participation

  • Subjects who are women of childbearing potential (those who are not surgically sterilized or postmenopausal) are excluded from participation in the investigation if they meet any one of the following conditions:

    • She is currently pregnant
    • She plans to become pregnant during the study
    • She is breastfeeding
  • Subjects with any systemic disease currently affecting ocular health or that, in the Investigator's opinion, may have an effect on ocular health during the course of the study

  • Subjects with an active ocular disease

  • Subjects who have had any corneal surgery (e.g., refractive surgery)

  • Subjects who have worn gas-permeable (GP) contact lenses within the last 30 days or who have worn polymethylmethacrylate (PMMA) lenses within the last 3 months

  • Subjects who currently wear monovision or toric contact lenses

  • Subjects who are not correctable to 32 letters (0.3 logMAR) with bilateral soft multifocal contact lenses

  • Subjects with an ocular astigmatism >1.00 D in either eye

  • Subjects with anisometropia (spherical equivalent) >2.00 D

  • Subjects with any Grade ≥2 finding during the slit lamp examination. Subjects with corneal infiltrates of ANY GRADE are not eligible

  • Any "Present" finding during the slit lamp examination that, in the Investigator's opinion, interferes with contact lens wear

  • Any scar or neovascularization within the central 6 mm of the cornea. Subjects with minor peripheral corneal scarring (that does not extend into the central area) that, in the Investigator's opinion, does not interfere with contact lens wear are eligible for this study

  • Subjects who are amblyopic

  • Subjects using any systemic or topical ocular medication that will, in the Investigator's opinion, affect ocular physiology or lens performance

  • Subjects who are allergic to any component in the study care products

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
e Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lensnew silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens-
Primary Outcome Measures
NameTimeMethod
Proportion of Subjects Agreeing With the Statement "Clear Vision: Near, Far, and In-between3 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (20)

Eola Eyes

🇺🇸

Orlando, Florida, United States

Pearle Vision

🇺🇸

Jacksonville, Florida, United States

Vision Health Institute

🇺🇸

Orlando, Florida, United States

The Eyecare Studio, LLC

🇺🇸

Decatur, Georgia, United States

Golden Vision

🇺🇸

Sarasota, Florida, United States

Family Eyecare Center

🇺🇸

Leavenworth, Kansas, United States

Cornea and Contact Lens Institute of Minnesota

🇺🇸

Edina, Minnesota, United States

Koetting Associates

🇺🇸

Saint Louis, Missouri, United States

Spectrum Eyecare

🇺🇸

Jamestown, New York, United States

Saccco Eye Group

🇺🇸

Vestal, New York, United States

Oculus Research

🇺🇸

Raleigh, North Carolina, United States

West Bay Eye Associates

🇺🇸

Warwick, Rhode Island, United States

CORE, Inc.

🇺🇸

Shelby, North Carolina, United States

Total Eye Care, PA

🇺🇸

Memphis, Tennessee, United States

Casco Bay EyeCare

🇺🇸

Portland, Maine, United States

Eric White OD Inc

🇺🇸

San Diego, California, United States

Lee & Woo Optometry

🇺🇸

San Francisco, California, United States

Chester T Roe III MD Prof LLC

🇺🇸

Denver, Colorado, United States

Optometric Physicians of Middle Tennessee

🇺🇸

Nashville, Tennessee, United States

Kannarr EyeCare

🇺🇸

Pittsburg, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath